Sanofi (NASDAQ: SNY) has recently experienced meaningful negative changes in fundamentals: significant quarterly sales deceleration occurred, the consensus estimate for December, 2023 decreased significantly, and the consensus estimate for December, 2024 decreased significantly.
Sanofi (NASDAQ: SNY) has recently experienced meaningful negative changes in investment behavior: the stock’s recent price decline challenged its longer term uptrend.
In light of these highly negative signals we are reviewing our current Overall Rating of C. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
SNY is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Sanofi has a current Value Trend Rating of C (Low Neutral). This rating combines contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Sanofi has a slightly positive Appreciation Score of 70 but a poor Power Rating of 25, triggering the Low Neutral Value Trend Rating.
Recent Price Action
Sanofi (NASDAQ: SNY) stock closed at $51.64 on 1/17/24 after a slight gain of 0.2%. However, below average trading volume at 73% of normal accompanied the advance. The stock has performed in line with the market over the last nine months and has declined -0.7% during the last week.
Be the first to comment